BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $14.17.

A number of research firms recently commented on BCRX. JMP Securities lifted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th.

BioCryst Pharmaceuticals Trading Up 0.4 %

BioCryst Pharmaceuticals stock opened at $7.46 on Tuesday. The firm has a 50-day moving average price of $7.83 and a 200-day moving average price of $6.62. The firm has a market capitalization of $1.54 billion, a PE ratio of -6.97 and a beta of 1.88. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The business had revenue of $109.30 million for the quarter, compared to analysts’ expectations of $98.30 million. During the same period last year, the business posted ($0.24) EPS. The company’s revenue for the quarter was up 34.9% on a year-over-year basis. As a group, sell-side analysts predict that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds have recently made changes to their positions in BCRX. CWM LLC grew its position in BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,772 shares during the period. Signaturefd LLC increased its stake in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,599 shares in the last quarter. Seven Eight Capital LP acquired a new position in BioCryst Pharmaceuticals during the first quarter worth $57,000. Natixis boosted its position in BioCryst Pharmaceuticals by 400.6% during the first quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 9,350 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in BioCryst Pharmaceuticals in the second quarter valued at $63,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.